Gene therapy takes on rare eye disease in Second-Eye trial
NCT ID NCT07586306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with Bietti's crystalline dystrophy, a rare genetic eye disease that causes vision loss. They have already received the gene therapy VGR-R01 in one eye. Now, researchers want to test if giving the same treatment to the other eye is safe and can improve vision. About 15 participants will be followed for side effects and changes in eyesight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
-
Shanghai General Hospital (Shanghai First People's Hospital)
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.